Mirati steps on the gas with KRAS inhibitor, looking to claim second approval behind Amgen’s Lumakras

Amgen beat Mirati to the finish line with the first-ever approved KRAS inhibitor back in May. But Mirati’s picking up the pace and says it could be looking to carve out a space on the market by the end of the year with what it thinks is the better of…

...

Click to view original post